Ketamine News and Research RSS Feed - Ketamine News and Research

One in every 17 college students smokes marijuana on daily or near-daily basis

One in every 17 college students smokes marijuana on daily or near-daily basis

Daily marijuana use among the nation's college students is on the rise, surpassing daily cigarette smoking for the first time in 2014. [More]
Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals AG today announced that it has acquired the exclusive rights to market Daraprim (pyrimethamine) in the U.S. from Impax Laboratories, Inc. The acquisition by Turing is part of a strategic effort focused on treatments for toxoplasmosis and other serious infectious diseases. The company also announced plans to invest in the development of new drug candidates for toxoplasmosis. [More]
Turing Pharmaceuticals completes $90 million Series A financing

Turing Pharmaceuticals completes $90 million Series A financing

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on discovering and developing treatments for serious and life-threatening diseases, today announced the completion of its Series A financing. The $90 million round was led by Martin Shkreli, Founder & Chief Executive Officer. [More]
Female patients with depression have abnormally high expression levels of glutamate receptor genes

Female patients with depression have abnormally high expression levels of glutamate receptor genes

Numerous genes that regulate the activity of a neurotransmitter in the brain have been found to be abundant in brain tissue of depressed females. This could be an underlying cause of the higher incidence of suicide among women, according to research at the University of Illinois at Chicago. [More]
Healthcare systems miss life-saving treatments learnt on battlefield

Healthcare systems miss life-saving treatments learnt on battlefield

Trauma is responsible for more global deaths annually than HIV, malaria and tuberculosis combined. Yet healthcare systems in many countries are missing out on life-saving treatments learnt on the battlefield, according to a review by King's College London and published today in the Journal of the Royal Society of Medicine. [More]
Good news for patients suffering from shingles

Good news for patients suffering from shingles

The Journal of Drugs in Dermatology is delighted to present new findings from the Mayo Clinic's Department of Dermatology showing possible relief from the complications and pain secondary to Herpes Zoster, commonly known as shingles. [More]
Neuroprotective compounds can limit damage to the brain during ischemic stroke

Neuroprotective compounds can limit damage to the brain during ischemic stroke

In the 1990s, neuroscientists identified a class of drugs that showed promise in the area of stroke. NMDA receptor antagonists could limit damage to the brain in animal models of stroke. But one problem complicated testing the drugs in a clinical setting: the side effects included disorientation and hallucinations. [More]
Study finds link between contraband cigarette and illicit drug use among teens in Canada

Study finds link between contraband cigarette and illicit drug use among teens in Canada

A University of Alberta economics professor has discovered a link between contraband cigarette use and illicit drug use among Canadian teens. [More]
Scientists receive NARSAD Distinguished Investigator Grants for mental health research

Scientists receive NARSAD Distinguished Investigator Grants for mental health research

The Brain & Behavior Research Foundation today announced the award of NARSAD Distinguished Investigator Grants valued at $1.5 million to 15 scientists, who are full professors or the equivalent, conducting innovative projects in diverse areas of neurobiological and behavioral research. [More]
Brain & Behavior Research Foundation to honor 8 scientists for achievements in psychiatric research

Brain & Behavior Research Foundation to honor 8 scientists for achievements in psychiatric research

The Brain & Behavior Research Foundation will honor eight scientists with its 2014 Outstanding Achievement Prizes for work delving into psychiatric disorders that affect one in four people. The awards, which celebrate the transformative power of neuroscience and psychiatric research to improve the lives of people with mental illness, will be presented at the Foundation's National Awards Dinner at the Pierre Hotel. [More]
RSAM, Rettsyndrome.org renew commitment to defeat Rett syndrome

RSAM, Rettsyndrome.org renew commitment to defeat Rett syndrome

Rett Syndrome Association of Massachusetts and Rettsyndrome.org are thrilled to announce today their renewed commitment to work together to defeat Rett syndrome. A generous $150,000 donation from RSAM will support a Rettsyndrome.org approved grant to Dr. Michela Fagiolini's project at the Boston Children's Hospital: "Assessing NMDA receptor (NMDAr) modulators to ameliorate cortical regression in Rett syndrome". [More]
New hope for people suffering from depression

New hope for people suffering from depression

There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug, according to a study in the July issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists- (ASA-). [More]
Researchers develop rapid-acting antidepressants for treatment-resistant depression

Researchers develop rapid-acting antidepressants for treatment-resistant depression

UT Southwestern Medical Center researchers have generated fresh insights that could aid in the development of rapid-acting antidepressants for treatment-resistant depression. [More]
Naurex's two lead antidepressant programs achieve major milestones

Naurex's two lead antidepressant programs achieve major milestones

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones. [More]
IV-administered ketamine effective in patients with chronic PTSD

IV-administered ketamine effective in patients with chronic PTSD

For the first time, evidence that a single dose of IV-administered ketamine was associated with the rapid reduction of symptoms of post-traumatic stress disorder in patients with chronic PTSD was demonstrated in a proof-of-concept, randomized, double blind crossover study, undertaken by researchers at the Icahn School of Medicine at Mount Sinai in New York City. These findings, according to Mount Sinai researchers, could be the first step toward developing new interventions for PTSD. [More]
Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect -within 24 hours-and was well tolerated in patients with treatment-resistant major depressive disorder. [More]

Ketamine offers novel treatment for patients with severe depression

New data show ketamine (a drug widely used for anaesthesia and pain relief) has a rapid antidepressant effect in some patients with severe depression. The first UK study of ketamine intravenous infusions in people with treatment-resistant depression was conducted by the Oxford Health NHS Foundation Trust and the University of Oxford. [More]
Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014. [More]
New treatments for depression on the horizon

New treatments for depression on the horizon

New insights into the physiological causes of depression are leading to treatments beyond common antidepressants such as Prozac and Zoloft, researchers are reporting in the in the journal Current Psychiatry. [More]
PET imaging of brain reveals ketamine may act as antidepressant by regulating serotonin activity

PET imaging of brain reveals ketamine may act as antidepressant by regulating serotonin activity

‚ÄčKetamine is a potent anesthetic employed in human and veterinary medicine, and sometimes used illegally as a recreational drug. The drug is also a promising candidate for the fast treatment of depression in patients who do not respond to other medications. [More]
Advertisement
Advertisement